116 related articles for article (PubMed ID: 25066387)
21. Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls.
Pasmans H; Schurink-Van't Klooster TM; Bogaard MJM; van Rooijen DM; de Melker HE; Welters MJP; van der Burg SH; van der Klis FRM; Buisman AM
Vaccine; 2019 Nov; 37(49):7280-7288. PubMed ID: 31575492
[TBL] [Abstract][Full Text] [Related]
22. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women.
Levi M; Bonanni P; Burroni E; Bechini A; Boccalini S; Sani C; Bonaiuti R; Indiani L; Azzari C; Lippi F; Carozzi F;
Hum Vaccin Immunother; 2013 Jul; 9(7):1407-12. PubMed ID: 23571176
[TBL] [Abstract][Full Text] [Related]
24. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
25. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
[TBL] [Abstract][Full Text] [Related]
26. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malaria.
Nakalembe M; Banura C; Namujju PB; Mirembe FM
J Infect Dev Ctries; 2015 Feb; 9(2):197-205. PubMed ID: 25699495
[TBL] [Abstract][Full Text] [Related]
28. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
Vesikari T; Van Damme P; Lindblad N; Pfletschinger U; Radley D; Ryan D; Vuocolo S; Haupt RM; Guris D
Pediatr Infect Dis J; 2010 Apr; 29(4):314-8. PubMed ID: 19952980
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.
Mok CC; Ho LY; Fong LS; To CH
Ann Rheum Dis; 2013 May; 72(5):659-64. PubMed ID: 22589375
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females.
Shi LW; Li J; Yu BW; Huang LR; Li K; Ji M; Zhou LY; Yuan L; Yang SY; Chen JJ; Wang L; Jiang ZW; Li RC; Li YP; Xia JL; Mo ZJ; Li CG
Hum Vaccin Immunother; 2023 Dec; 19(1):2209001. PubMed ID: 37249310
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study.
Grein IHR; Pinto NBF; Groot N; Martins CB; Lobo A; Aikawa NE; Barbosa C; Terreri MT; da Fraga ACM; de Oliveira SKF; Sztajnbok F; Paim Marques LB; Islabão AG; Appenzeller S; Bica B; de Oliveira Sato J; Magalhães CS; Ferriani V; Pasmans H; Schepp R; van der Klis F; de Roock S; Wulffraat N; Pileggi GS
Pediatr Rheumatol Online J; 2020 Nov; 18(1):87. PubMed ID: 33176806
[TBL] [Abstract][Full Text] [Related]
33. HPV 6, 11, 16, 18 vaccine in men. Inadequate assessment.
Prescrire Int; 2012 Sep; 21(130):208. PubMed ID: 23016251
[TBL] [Abstract][Full Text] [Related]
34. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
35. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):626-9. PubMed ID: 20508593
[TBL] [Abstract][Full Text] [Related]
36. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
Grimaldi-Bensouda L; Guillemot D; Godeau B; Bénichou J; Lebrun-Frenay C; Papeix C; Labauge P; Berquin P; Penfornis A; Benhamou PY; Nicolino M; Simon A; Viallard JF; Costedoat-Chalumeau N; Courcoux MF; Pondarré C; Hilliquin P; Chatelus E; Foltz V; Guillaume S; Rossignol M; Abenhaim L;
J Intern Med; 2014 Apr; 275(4):398-408. PubMed ID: 24206418
[TBL] [Abstract][Full Text] [Related]
37. Long-term study of a quadrivalent human papillomavirus vaccine.
Ferris D; Samakoses R; Block SL; Lazcano-Ponce E; Restrepo JA; Reisinger KS; Mehlsen J; Chatterjee A; Iversen OE; Sings HL; Shou Q; Sausser TA; Saah A
Pediatrics; 2014 Sep; 134(3):e657-65. PubMed ID: 25136050
[TBL] [Abstract][Full Text] [Related]
38. Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages.
Chen Q; Zhao H; Yao X; Lin Z; Li J; Lin B; Wang R; Huang Y; Su Y; Wu T; Li C; Pan H; Huang S; Zhang J; Xia N
Vaccine; 2020 Sep; 38(39):6096-6102. PubMed ID: 32718817
[TBL] [Abstract][Full Text] [Related]
39. Assessing human papillomavirus vaccine efficacy and safety.
Hendrix SL
J Am Osteopath Assoc; 2008 Apr; 108(4 Suppl 2):S8-S12. PubMed ID: 18463363
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.
Krajden M; Cook D; Yu A; Chow R; Mei W; McNeil S; Money D; Dionne M; Karunakaran KP; Palefsky JM; Dobson S; Ogilvie G; Petric M
Clin Vaccine Immunol; 2011 Mar; 18(3):418-23. PubMed ID: 21248158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
